CN113149022A - Silica @ calcium silicate hollow nanosphere and preparation method and application thereof - Google Patents
Silica @ calcium silicate hollow nanosphere and preparation method and application thereof Download PDFInfo
- Publication number
- CN113149022A CN113149022A CN202110478939.9A CN202110478939A CN113149022A CN 113149022 A CN113149022 A CN 113149022A CN 202110478939 A CN202110478939 A CN 202110478939A CN 113149022 A CN113149022 A CN 113149022A
- Authority
- CN
- China
- Prior art keywords
- hollow
- casio
- nanospheres
- sio
- mesoporous silica
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/20—Silicates
- C01B33/24—Alkaline-earth metal silicates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/113—Silicon oxides; Hydrates thereof
- C01B33/12—Silica; Hydrates thereof, e.g. lepidoic silicic acid
- C01B33/14—Colloidal silica, e.g. dispersions, gels, sols
- C01B33/146—After-treatment of sols
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/03—Particle morphology depicted by an image obtained by SEM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/01—Particle morphology depicted by an image
- C01P2004/04—Particle morphology depicted by an image obtained by TEM, STEM, STM or AFM
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/30—Particle morphology extending in three dimensions
- C01P2004/32—Spheres
- C01P2004/34—Spheres hollow
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2004/00—Particle morphology
- C01P2004/80—Particles consisting of a mixture of two or more inorganic phases
- C01P2004/82—Particles consisting of a mixture of two or more inorganic phases two phases having the same anion, e.g. both oxidic phases
- C01P2004/84—Particles consisting of a mixture of two or more inorganic phases two phases having the same anion, e.g. both oxidic phases one phase coated with the other
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01P—INDEXING SCHEME RELATING TO STRUCTURAL AND PHYSICAL ASPECTS OF SOLID INORGANIC COMPOUNDS
- C01P2006/00—Physical properties of inorganic compounds
- C01P2006/16—Pore diameter
Abstract
The invention provides a silicon dioxide @ calcium silicate hollow nanosphere and a preparation method and application thereof, and relates to the technical field of drug sustained-release microspheres. The SiO provided by the invention2@CaSiO3The hollow nanospheres take hollow mesoporous silica nanospheres as core layers and calcium silicate as shell layers; the SiO2@CaSiO3The hollow nanospheres are distributed with a plurality of through holes which are communicated with the outside, and part of the through holes are communicated with the hollow structure of the core layer. The SiO provided by the invention2@CaSiO3The hollow nanospheres have high encapsulation efficiency and high drug loading rateThe biological pH-sensitive hydrogel is nontoxic, harmless, good in biocompatibility, good in degradability in a human body and excellent in pH response capability at a special position.
Description
Technical Field
The invention relates to the technical field of drug sustained-release microspheres, in particular to a silicon dioxide @ calcium silicate hollow nanosphere and a preparation method and application thereof.
Background
Calcium silicate (CaSiO)3Calcium Silicate) is an important inorganic component of human bones and teeth, and is widely applied to the research of drug sustained-release carriers because of good biocompatibility and biosafety. CaSiO in contrast to viral vectors3The inorganic carrier has no immunogenicity, and does not cause immune response to organisms; at the same time, CaSiO3Has good biodegradability, and the degradation period of the biodegradable material is closely related to the physical and chemical properties of the material.
Chinese patent CN110693851A discloses mesoporous silica drug-loaded nanoparticles, a preparation method and an application thereof, wherein mesoporous silica is used as a drug-loaded carrier, a polydopamine layer is wrapped outside the mesoporous silica carrier, and a tumor-oriented penetration peptide iRGD and poly (2-ethyl-2-oxazoline) are connected through Schiff base addition reaction for loading anticancer drugs, but the material stability is poor, and the sustained-release effect is not ideal after the drugs are basically released within 24 hours. Chinese patent CN109589418A discloses a Schiff base copolymer coated mesoporous silica drug-loaded nanoparticle with pH responsiveness, and a preparation method and application thereof.
Disclosure of Invention
The invention aims to provide a silicon dioxide @ calcium silicate hollow nanosphere and a preparation method and application thereof, and the SiO provided by the invention2@CaSiO3The hollow nanosphere has high encapsulation efficiency, high drug loading rate, no toxicity, no harm, good biocompatibility, good slow release effect, good degradability in human body, and excellent pH response capability at special parts (in acidic body fluid environment such as human stomach).
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides SiO2@CaSiO3The hollow nanospheres take hollow mesoporous silica nanospheres as core layers and calcium silicate as shell layers; the SiO2@CaSiO3The hollow nanospheres are distributed with a plurality of through holes which are communicated with the outside, and part of the through holes are communicated with the hollow structure of the core layer.
Preferably, the SiO2@CaSiO3The particle size of the hollow nanospheres is 300-500 nm.
Preferably, the diameter of the hollow structure of the nuclear layer is 200-300 nm; the aperture of the through hole is 4-6 nm.
Preferably, the calcium silicate is SiO in mass2@CaSiO35-10% of the total mass of the hollow nanospheres.
The invention provides the SiO in the technical scheme2@CaSiO3The preparation method of the hollow nanosphere comprises the following steps:
dispersing hollow mesoporous silica nanospheres in water to obtain silica nanosphere dispersion liquid;
mixing the silicon dioxide nanosphere dispersion liquid with a surfactant to obtain a modified silicon dioxide nanosphere dispersion liquid;
mixing the modified silicon dioxide nanosphere dispersion liquid with an alkaline substance, adjusting the pH value of a system to be 12-13, adding a calcium source, and carrying out a precipitation reaction to obtain SiO2@CaSiO3Hollow nanospheres.
Preferably, the mass ratio of the surfactant to the hollow mesoporous silica nanospheres is 2-7: 10-20.
Preferably, the mass ratio of the calcium source to the hollow mesoporous silica nanospheres is 6-9: 5-10.
Preferably, the temperature of the precipitation reaction is 70-100 ℃; the precipitation reaction time is 2-5 h.
The invention provides the SiO in the technical scheme2@CaSiO3Hollow nanospheres or SiO prepared by the preparation method of the technical scheme2@CaSiO3The hollow nanospheres are applied to the field of drug-loading sustained release.
Preferably, the drug is loaded on the SiO2@CaSiO3The through hole of the hollow nanosphere and the hollow structure of the core layer.
The invention provides SiO2@CaSiO3The hollow nanospheres take hollow mesoporous silica nanospheres as core layers and calcium silicate as shell layers; the SiO2@CaSiO3The hollow nanospheres are distributed with a plurality of through holes which are communicated with the outside, and part of the through holes are communicated with the hollow structure of the core layer. In the invention, the silicon dioxide and the calcium silicate are inorganic salt carrier materials, the chemical composition of the inorganic salt carrier materials is similar to the mineral composition of hard tissues such as human bones, teeth and the like, and the biocompatibility, the osteoconductivity and the degradability are good; adsorption of drugs to SiO in vitro2@CaSiO3After the hollow nanospheres are arranged in the through holes and the hollow structures, the SiO loaded with the medicine is injected2@CaSiO3The hollow nanospheres are implanted in vivo, and due to low drug concentration in body fluid, the drug gradually comes from SiO2@CaSiO3The hollow nanospheres are released from the interior to achieve the purpose of exerting the drug effect for a long time; the hollow structure of the nuclear layer can greatly improve SiO2@CaSiO3The hollow nanospheres have drug loading capacity, so that the drug sustained-release system has the advantages of good drug loading performance, drug sustained-release performance and the like, and can safely, slowly and efficiently control the drug to be released as required; under the condition of low pH, the shell layer CaSiO3The damage is caused, the release speed and the release amount of the drug are improved, and the effect of pH response is achieved.
Drawings
FIG. 1 is SiO according to the present invention2@CaSiO3Reaction schematic diagram of hollow nanospheres;
FIG. 2 is a scanning electron microscope image of the hollow mesoporous silica nanospheres of the present invention;
FIG. 3 is SiO according to the present invention2@CaSiO3Scanning electron micrographs of hollow nanospheres;
FIG. 4 shows SiO in test example 12@CaSiO3Hollow nanosphere loaded DOX concentration standard curveLine drawing;
FIG. 5 shows SiO in test example 22@CaSiO3A release curve graph of hollow nanosphere loaded DOX accumulated in PBS buffer solution;
FIG. 6 shows SiO prepared by the present invention2@CaSiO3Transmission electron microscopy images of hollow nanospheres.
Detailed Description
The invention provides SiO2@CaSiO3The hollow nanospheres take hollow mesoporous silica nanospheres as core layers and calcium silicate as shell layers; the SiO2@CaSiO3The hollow nanospheres are distributed with a plurality of through holes which are communicated with the outside, and part of the through holes are communicated with the hollow structure of the core layer.
In the invention, the particle size of the hollow mesoporous silica nanosphere is preferably 300-500 nm, and more preferably 300-400 nm; the diameter of the hollow structure of the hollow mesoporous silica nanosphere is preferably 200-300 nm, and more preferably 200 nm. In the invention, mesopores are distributed on the surface of the hollow mesoporous silica nanospheres, and the aperture is preferably 4-6 nm; part of the mesopores are communicated with the hollow structure of the hollow mesoporous silica nanospheres.
In the present invention, the calcium silicate is preferably SiO in mass2@CaSiO3The total mass of the hollow nanospheres is 5-10%, and more preferably 6-8%.
In the present invention, the SiO2@CaSiO3The particle size of the hollow nanospheres is preferably 300-500 nm, and more preferably 400-500 nm. In the present invention, the SiO2@CaSiO3The aperture of the through hole of the hollow nanosphere is preferably 4-6 nm, and more preferably 6 nm.
The invention also provides the SiO in the technical scheme2@CaSiO3The preparation method of the hollow nanosphere comprises the following steps:
dispersing hollow mesoporous silica nanospheres in water to obtain silica nanosphere dispersion liquid;
mixing the silicon dioxide nanosphere dispersion liquid with a surfactant to obtain a modified silicon dioxide nanosphere dispersion liquid;
mixing the modified silicon dioxide nanosphere dispersion liquid with an alkaline substance, adjusting the pH value of a system to be 12-13, adding a calcium source, and carrying out a precipitation reaction to obtain SiO2@CaSiO3Hollow nanospheres.
The invention disperses the hollow mesoporous silicon dioxide nanospheres in water to obtain the silicon dioxide nanosphere dispersion liquid. In the present invention, the structure of the hollow mesoporous silica nanospheres is consistent with that of the hollow mesoporous silica nanospheres as the core layer, which is not described herein again. In the invention, the dosage ratio of the hollow mesoporous silica nanospheres to water is preferably 1-2 g: 2-4L, more preferably 1.5 g: 2.5L.
The preparation method of the hollow mesoporous silica nanosphere has no special requirements, and the hollow mesoporous silica nanosphere can be prepared by a preparation method well known by the technical personnel in the field, and particularly preferably by an improved stober method. In the present invention, the preparation method of the hollow mesoporous silica nanosphere preferably comprises the following steps:
mixing ethanol, water, ammonia water and hexadecyl trimethyl ammonium bromide to obtain a mixed solution;
dropwise adding ethyl orthosilicate into the mixed solution, and carrying out water bath reaction to obtain mesoporous silica nanospheres;
and mixing the mesoporous silica nanospheres with water, and stirring and refluxing to obtain the hollow mesoporous silica nanospheres.
In the present invention, the mass concentration of the ammonia water is preferably 30%; the volume ratio of the ethanol to the water to the ammonia water is preferably 30:50: 1. In the present invention, the ratio of the amount of ethanol to the amount of cetyltrimethylammonium bromide is preferably 1 mL: 5 mg. According to the invention, ethanol, water and ammonia water are preferably uniformly mixed at room temperature, and then cetyl trimethyl ammonium bromide is added for ultrasonic dispersion to obtain a mixed solution. In the present invention, the power of the ultrasonic dispersion is preferably 40hHz, and the time is preferably 30 min.
After the mixed solution is obtained, the invention preferably drops ethyl orthosilicate in the mixed solution to carry out water bath reaction to obtain the mesoporous silica nanosphere. In the present invention, the volume ratio of ethanol to ethyl orthosilicate is preferably 30: 1. In the present invention, the dropping rate of the tetraethoxysilane is preferably 1 mL/min. In the present invention, the temperature of the water bath reaction is preferably 35 ℃; the time of the water bath reaction is preferably 24 hours.
According to the invention, preferably, after the water bath reaction, the obtained solid product is washed and dried to obtain the mesoporous silica nanosphere. In the present invention, the washing method is preferably a method of centrifuging and washing with water and ethanol several times. The invention removes unreacted ammonia water and cetyl trimethyl ammonium bromide by washing. In the invention, the drying temperature is preferably 60-90 ℃, and more preferably 70-80 ℃; the drying time is preferably 24 h.
After the mesoporous silica nanospheres are obtained, the mesoporous silica nanospheres are preferably mixed with water, and stirred and refluxed to obtain the hollow mesoporous silica nanospheres. In the invention, the mass ratio of the mesoporous silica nanospheres to water is preferably 1: 200; the water is preferably deionized water. In the present invention, the stirring speed of the stirring reflux is preferably 500 rpm; the temperature of the stirring reflux is preferably 70 ℃; the stirring reflux is preferably carried out under oil bath conditions; the stirring and refluxing time is preferably 18-20 h.
According to the invention, preferably, after the stirring and refluxing, the obtained product is sequentially washed and dried to obtain the hollow mesoporous silica nanospheres. In the present invention, the washing method preferably includes multiple centrifugal washing with water and ethanol. In the invention, the drying temperature is preferably 60-90 ℃, and more preferably 70-80 ℃; the drying time is preferably 12-24 h.
The invention prepares mesoporous silica nanospheres with uniform particle size and average particle size of 300nm by an improved stober method, and obtains hollow mesoporous silica nanospheres after refluxing in water for a certain time.
After the hollow mesoporous silica nanospheres are dispersed in water to obtain silica nanosphere dispersion liquid, the silica nanosphere dispersion liquid is mixed with a surfactant to obtain modified silica nanosphere dispersion liquid. In the present invention, the surfactant preferably includes one or more of cetyltrimethylammonium bromide, polyvinylpyrrolidone, octadecyldimethylhydroxyethylammonium and dodecyldimethylbenzylammonium chloride, and more preferably cetyltrimethylammonium bromide. In the invention, the mass ratio of the surfactant to the hollow mesoporous silica nanospheres is preferably 2-7: 10-20, and more preferably 1.5-2.5: 10.
In the invention, the mixing of the silicon dioxide nanosphere dispersion liquid and the surfactant is preferably carried out under the stirring condition, and the stirring speed is preferably 300-500 rpm, and more preferably 400 rpm; the stirring time is preferably 10-40 min, and more preferably 30 min. In the present invention, the mixing is preferably performed at room temperature, and particularly preferably at 25 ℃. In the mixing process, the surfactant is combined with silicon hydroxyl on the surface of the silicon dioxide to obtain the modified silicon dioxide nanosphere.
After the modified silicon dioxide nanosphere dispersion liquid is obtained, the modified silicon dioxide nanosphere dispersion liquid is mixed with alkaline substances, the pH value of a system is adjusted to be 12-13, a calcium source is added, and precipitation reaction is carried out to obtain SiO2@CaSiO3Hollow nanospheres. In the present invention, the basic substance preferably includes sodium hydroxide, sodium acetate or ammonia water, more preferably sodium hydroxide; when the alkaline substance is ammonia water, the mass concentration of the ammonia water is preferably 30%. In the present invention, the amount of the alkaline substance added is preferably such that the pH of the system is 12 to 13. According to the invention, alkaline substances are added to provide an alkaline environment for the system, and the surface of the modified silicon dioxide nanosphere can be etched to generate silicate ions.
In the present invention, the calcium source preferably comprises calcium nitrate, calcium chloride or calcium sulfate, more preferably calcium nitrate. In the invention, the mass ratio of the calcium source to the hollow mesoporous silica nanospheres is preferably 6-9: 5-10, and more preferably 5-8: 10.
In the invention, the temperature of the precipitation reaction is preferably 70-100 ℃, and more preferably 80-95 ℃; the time of the precipitation reaction is preferably 2-6 h, and more preferably 3-5 h. In the present invention, the precipitation reaction is carried out under stirring conditions, preferably at a rate of 400 rpm. In the precipitation reaction process, the calcium source reacts with silicate ions generated after the silicon dioxide is etched to generate calcium silicate, and the calcium silicate is deposited on the surface of the etched hollow mesoporous silicon dioxide nanospheres.
According to the invention, after the precipitation reaction, the obtained product is preferably washed and dried in sequence to obtain SiO2@CaSiO3Hollow nanospheres. In the present invention, the method of washing preferably comprises: washing with water and ethanol repeatedly, and centrifuging. The invention has no special requirement on the washing times, and the conventional washing method of the technicians in the field can be adopted. In the invention, the drying is preferably vacuum drying, and the drying temperature is preferably 60-90 ℃, and more preferably 70-80 ℃; the drying time is preferably 24 h.
The invention also provides the SiO in the technical scheme2@CaSiO3Hollow nanospheres or SiO prepared by the preparation method of the technical scheme2@CaSiO3The hollow nanospheres are applied to the field of drug-loading sustained release. In the present invention, the drug is preferably supported on SiO2@CaSiO3The through hole of the hollow nanosphere and the hollow structure of the core layer. In the present invention, the loaded drug preferably comprises doxorubicin (C)27H29NO11Doxorubicin, DOX) and/or curcumin.
In the present invention, the SiO2@CaSiO3The method for loading the hollow nanospheres with the medicament is preferably mixing, and particularly preferably: subjecting the SiO2@CaSiO3Mixing hollow nanosphere with dispersion or solution containing drug, stirring at room temperature to adsorb drug, centrifuging, and drying to obtain drug-loaded SiO2@CaSiO3Hollow nanospheres. In the invention, the stirring time is preferably 24-48 h.
In a specific embodiment of the invention, each gram of said SiO2@CaSiO3The drug loading capacity of the hollow nanospheres is preferably 0.08-0.10 g; what is needed isThe SiO2@CaSiO3The encapsulation rate of the hollow nanospheres is preferably more than 80%, and more preferably 82-92%.
SiO2@CaSiO3The hollow nanosphere has the advantages of large specific surface area, good biocompatibility and the like due to the hollow structure and the through holes, and has the advantages of high drug loading rate, high entrapment rate, small side effect and the like when being used as a drug slow-release carrier. The invention adsorbs the medicine to SiO in vitro2@CaSiO3After the hollow nanospheres are arranged in the through holes and the hollow structures, the SiO loaded with the medicine is injected2@CaSiO3The hollow nanospheres are implanted in vivo, and due to low drug concentration in body fluid, the drug gradually comes from SiO2@CaSiO3The hollow nanospheres are released from the interior to achieve the purpose of exerting the drug effect for a long time; the hollow structure of the nuclear layer can greatly improve SiO2@CaSiO3The hollow nanospheres have drug loading capacity, so that the drug sustained-release system has the advantages of good drug loading performance, drug sustained-release performance and the like, and can safely, slowly and efficiently control the drug to be released as required. The invention controls SiO2@CaSiO3The shape and the particle size of the hollow nanosphere can effectively control the drug release percentage and the slow release rate and prolong the drug treatment time, in the invention, SiO2@CaSiO3The more regular the spherical structure of the hollow nanosphere is, the more uniform the spherical structure is when the hollow nanosphere is taken as a carrier or injected into a human body, and the hollow nanosphere is more favorable for transporting drugs.
The technical solution of the present invention will be clearly and completely described below with reference to the embodiments of the present invention. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Example 1
Uniformly mixing 30mL of ethanol and 50mL of water, dispersing 150mg of hexadecyl trimethyl ammonium bromide in a mixed solvent, adding 1mL of ammonia water with the mass concentration of 30%, dropwise adding 1mL of tetraethoxysilane under rapid stirring, carrying out water bath reaction on the obtained mixed solution at the temperature of 35 ℃ for 24 hours, washing and centrifuging the mesoporous silica microspheres obtained after the reaction is finished by using water and ethanol, and transferring the mesoporous silica microspheres into a vacuum drying oven to dry at the temperature of 70 ℃ for 24 hours to obtain mesoporous silica nanospheres;
dispersing 2g of the mesoporous silica nanospheres in 400mL of water, stirring and refluxing for 20h at 70 ℃, repeatedly washing with water and ethanol after the reaction is finished, centrifuging, and transferring to a vacuum drying oven to dry for 24h at 70 ℃ to obtain the hollow mesoporous silica nanospheres.
Preparation of SiO by the method shown in FIG. 12@CaSiO3Hollow nanospheres: dispersing 100mg of the hollow mesoporous silica nanospheres in 150mL of water to obtain silica nanosphere dispersion liquid;
adding 25mg of hexadecyl trimethyl ammonium bromide into the silicon dioxide nanosphere dispersion liquid under stirring, and stirring at a constant speed of 25 ℃ for 30min to obtain a modified silicon dioxide nanosphere dispersion liquid;
adding sodium hydroxide into the modified silicon dioxide nanosphere dispersion liquid for etching, adjusting the pH value to 12, then adding 80mg of calcium nitrate, reacting for 3 hours at the temperature of 95 ℃ under uniform stirring, repeatedly washing a solid product obtained after the reaction with water and ethanol, centrifuging, transferring into a vacuum drying oven, and drying for 24 hours at the temperature of 70 ℃ to obtain SiO2@CaSiO3Hollow nanospheres.
FIG. 2 is a scanning electron microscope image of the hollow mesoporous silica nanospheres of the present invention. As can be seen from FIG. 2, the hollow mesoporous silica nanospheres prepared by the method have uniform particle size, and the average particle size is 500 nm.
FIG. 3 is SiO according to the present invention2@CaSiO3Scanning electron micrographs of hollow nanospheres. As can be seen from FIG. 3, the SiO prepared by the present invention2@CaSiO3The hollow nanospheres have hollow structures inside and porous surfaces.
FIG. 6 shows SiO of the present invention2@CaSiO3Transmission electron microscopy images of hollow nanospheres. As can be seen from FIG. 6, SiO2@CaSiO3The hollow nanospheres are in a hollow double-shell structure and have relatively high colorDeep of SiO2The outermost layer is shallower CaSiO3。
SiO prepared in this example2@CaSiO3The average particle diameter of the hollow nanospheres is 500nm, and the SiO is2@CaSiO3A plurality of through holes are distributed on the hollow nanospheres, and the aperture of each through hole is 6 nm.
Example 2
Preparing hollow mesoporous silica nanospheres according to the method of example 1;
dispersing 100mg of the hollow mesoporous silica nanospheres in 150mL of water to obtain silica nanosphere dispersion liquid;
adding 15mg of hexadecyl trimethyl ammonium bromide into the silicon dioxide nanosphere dispersion liquid under stirring, and stirring at a constant speed of 25 ℃ for 30min to obtain a modified silicon dioxide nanosphere dispersion liquid;
adding sodium hydroxide into the modified silicon dioxide nanosphere dispersion liquid for etching, adjusting the pH value to 12, then adding 50mg of calcium nitrate, reacting for 6 hours at 80 ℃ under the condition of uniform stirring, repeatedly washing a solid product obtained after the reaction with water and ethanol, centrifuging, transferring into a vacuum drying oven, and drying for 24 hours at 70 ℃ to obtain SiO2@CaSiO3Hollow nanospheres.
SiO prepared in this example2@CaSiO3The average particle diameter of the hollow nanospheres is 400nm, and the SiO is2@CaSiO3A plurality of through holes are distributed on the hollow nanospheres, and the aperture of each through hole is 4 nm.
Example 3
Preparing hollow mesoporous silica nanospheres according to the method of example 1;
dispersing 100mg of the hollow mesoporous silica nanospheres in 150mL of water to obtain silica nanosphere dispersion liquid;
adding 25mg of hexadecyl trimethyl ammonium bromide into the silicon dioxide nanosphere dispersion liquid under stirring, and stirring at a constant speed of 25 ℃ for 30min to obtain a modified silicon dioxide nanosphere dispersion liquid;
adding sodium acetate into the modified silicon dioxide nanosphere dispersion liquid for etching and adjustingAdjusting pH to 12, adding 80mg of calcium nitrate, reacting for 3h at 95 ℃ under uniform stirring, repeatedly washing the solid product obtained after the reaction with water and ethanol, centrifuging, transferring to a vacuum drying oven, and drying for 24h at 70 ℃ to obtain SiO2@CaSiO3Hollow nanospheres.
SiO prepared in this example2@CaSiO3The average particle diameter of the hollow nanospheres is 500nm, and the SiO is2@CaSiO3A plurality of through holes are distributed on the hollow nanospheres, and the aperture of each through hole is 4 nm.
Test example 1
For the SiO prepared in examples 1 to 3, respectively2@CaSiO3The hollow nanospheres were tested for DOX encapsulation efficiency and drug loading:
the SiO prepared in examples 1 to 3 were weighed separately2@CaSiO3Respectively putting 50mg hollow nanospheres into 3 DOX solutions with the concentration of 1mg/mL and 5mL respectively, and uniformly mixing for 48h in a dark place to obtain DOX-loaded SiO2@CaSiO3Hollow nanospheres; separating with ultracentrifuge, collecting supernatant, washing with deionized water for three times (1 mL each time), centrifuging, and collecting supernatant. Measuring the OD480 value of the supernatant by using an ultraviolet spectrophotometer, wherein the OD480 value refers to setting the ultraviolet absorption wavelength to 480nm, and performing an ultraviolet absorbance test on the supernatant to obtain a test result; calculation of SiO by DOX concentration calibration Curve as shown in FIG. 42@CaSiO3The drug loading and encapsulation efficiency of the hollow nanospheres are calculated according to the following formula, and the obtained results are shown in table 1:
in formula I and formula II, the initial DOX mass is 5mg, and the supernatant DOX mass refers to the mass of DOX in the supernatant.
TABLE 1 prepared in examples 1 to 3SiO2@CaSiO3Detection result of DOX encapsulation rate and drug loading capacity of hollow nanospheres
| Sample number | Drug loading | Encapsulation efficiency (%) |
| Example 1 | 0.0916 | 91.623 |
| Example 2 | 0.0826 | 82.565 |
| Example 3 | 0.0855 | 85.474 |
As can be seen from Table 1, per gram of the SiO2@CaSiO3The drug loading capacity of the hollow nanospheres is 0.08-0.10 g; the SiO2@CaSiO3The encapsulation rate of the hollow nanospheres is more than 80%. The SiO provided by the invention2@CaSiO3The hollow nanosphere has high encapsulation efficiency, high drug loading rate, no toxicity, no harm and good biocompatibility.
Test example 2
For SiO prepared in example 32@CaSiO3The hollow nanospheres are subjected to in vitro drug release capability investigation at different pH values by the following method:
50mg of SiO prepared in example 3 are introduced2@CaSiO3Placing the hollow nanospheres in 5mL of DOX solution with the concentration of 1mg/mL, keeping out of the sun, and uniformly mixing for 48h to obtain DOX-loaded SiO2@CaSiO3Hollow nanospheres; two portions of 10mg of the DOX-loaded SiO2@CaSiO3The hollow nanospheres are respectively placed into 2 dialysis bags with the cut-off molecular weight of 8000-10000, then respectively placed into 30mL PBS solution with the pH value adjusted to 7.4 and 4.5 by 0.5% HCl, and placed into water bath at 37 ℃ for magnetic stirring to perform in-vitro drug slow release experiments. 1mL of the sustained release solution was taken out at release times of 1, 2, 4, 6, 12, 24, 36, 48, 60, 72, 84, 96, 108 and 120h, respectively, and then 1mL of PBS solution of the same pH was supplemented, and the OD480 value of the sustained release solution at each time point was measured using an ultraviolet spectrophotometer, as shown in FIG. 5.
As can be seen from FIG. 5, the burst release of the drug occurs under different pH conditions before 20 hours, and the drug release is carried out slowly in the subsequent time, so that the effect of long-term and effective drug release is achieved. Under the environment of pH 4.5, the surface CaSiO3The shell layer is damaged to a certain extent, so that the drug release rate and the accumulated drug release amount are increased along with the reduction of the pH value, and the material is proved to have a certain pH response effect.
The foregoing is only a preferred embodiment of the present invention, and it should be noted that, for those skilled in the art, various modifications and decorations can be made without departing from the principle of the present invention, and these modifications and decorations should also be regarded as the protection scope of the present invention.
Claims (10)
1. SiO (silicon dioxide)2@CaSiO3The hollow nanospheres take hollow mesoporous silica nanospheres as core layers and calcium silicate as shell layers; the SiO2@CaSiO3The hollow nanospheres are distributed with a plurality of through holes which are communicated with the outside, and part of the through holes are communicated with the hollow structure of the core layer.
2. SiO as claimed in claim 12@CaSiO3Hollow nanospheres characterized in that said SiO2@CaSiO3The particle size of the hollow nanospheres is 300-500 nm.
3. SiO according to claim 1 or 22@CaSiO3The hollow nanospheres are characterized in that the diameter of the hollow structure of the core layer is 200-300 nm; the aperture of the through hole is 4-6 nm.
4. SiO as claimed in claim 12@CaSiO3Hollow nanospheres characterized in that the calcium silicate comprises SiO by mass2@CaSiO35-10% of the total mass of the hollow nanospheres.
5. SiO as claimed in any one of claims 1 to 42@CaSiO3The preparation method of the hollow nanosphere comprises the following steps:
dispersing hollow mesoporous silica nanospheres in water to obtain silica nanosphere dispersion liquid;
mixing the silicon dioxide nanosphere dispersion liquid with a surfactant to obtain a modified silicon dioxide nanosphere dispersion liquid;
mixing the modified silicon dioxide nanosphere dispersion liquid with an alkaline substance, adjusting the pH value of a system to be 12-13, adding a calcium source, and carrying out a precipitation reaction to obtain SiO2@CaSiO3Hollow nanospheres.
6. The preparation method of claim 5, wherein the mass ratio of the surfactant to the hollow mesoporous silica nanospheres is 2-7: 10-20.
7. The preparation method according to claim 5 or 6, wherein the mass ratio of the calcium source to the hollow mesoporous silica nanospheres is 6-9: 5-10.
8. The preparation method according to claim 5, wherein the temperature of the precipitation reaction is 70-100 ℃; the precipitation reaction time is 2-5 h.
9. Any one of claims 1 to 4The SiO2@CaSiO3Hollow nanospheres or SiO obtained by the preparation method according to any of claims 5 to 82@CaSiO3The hollow nanospheres are applied to the field of drug-loading sustained release.
10. The use of claim 9, wherein the drug is loaded on the SiO2@CaSiO3The through hole of the hollow nanosphere and the hollow structure of the core layer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110478939.9A CN113149022B (en) | 2021-04-30 | 2021-04-30 | Silica @ calcium silicate hollow nanosphere and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110478939.9A CN113149022B (en) | 2021-04-30 | 2021-04-30 | Silica @ calcium silicate hollow nanosphere and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113149022A true CN113149022A (en) | 2021-07-23 |
| CN113149022B CN113149022B (en) | 2022-07-22 |
Family
ID=76872695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110478939.9A Active CN113149022B (en) | 2021-04-30 | 2021-04-30 | Silica @ calcium silicate hollow nanosphere and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113149022B (en) |
Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1245091A (en) * | 1958-12-31 | 1960-11-04 | Du Pont | Pesticide compositions, in particular herbicides, based on polychlorophenylacetic acids or on compounds of these acids |
| US6132773A (en) * | 1996-04-22 | 2000-10-17 | Rhodia Chimie | Method for preparing particles comprising a core and a silica shell |
| JP2007230794A (en) * | 2006-02-28 | 2007-09-13 | National Institute Of Advanced Industrial & Technology | Hollow particle with unique shell and its production method |
| CN101121519A (en) * | 2006-08-08 | 2008-02-13 | 中国科学院理化技术研究所 | Hollow silicon dioxide sub-micron sphere with inner core and its preparation method and use |
| CN101161250A (en) * | 2006-10-12 | 2008-04-16 | 丛繁滋 | A novel enteron pharmaceutical preparation and its preparing method |
| WO2009023697A2 (en) * | 2007-08-14 | 2009-02-19 | The Regents Of The University Of California | Hollow silica nanospheres and methods of making same |
| CN101407597A (en) * | 2007-10-12 | 2009-04-15 | 上海化工研究院 | Halogen-free flame-retardant photo-curing epoxy resin composition |
| US20110059148A1 (en) * | 2009-09-07 | 2011-03-10 | National Chiao Tung University | Flexible Drug Delivery Chip, its Fabrication Method and Uses Thereof |
| CN102115087A (en) * | 2010-12-31 | 2011-07-06 | 张胜勇 | Method for producing silicon dioxide and calcium silicate by phosphorus residue |
| CN102451468A (en) * | 2010-10-28 | 2012-05-16 | 沈阳药科大学 | SiO2 mesoporous hollow nanosphere carrier and preparation and application thereof |
| US20130225877A1 (en) * | 2012-02-29 | 2013-08-29 | Celanese International Corporation | Catalyst Having Support Containing Tin and Process for Manufacturing Ethanol |
| CN103881713A (en) * | 2012-12-20 | 2014-06-25 | 海洋王照明科技股份有限公司 | Core-shell structured calcium silicate luminescent material and preparation method thereof |
| CN103920153A (en) * | 2014-05-06 | 2014-07-16 | 中国科学院上海硅酸盐研究所 | Chitosan-modified pH responsive medicine-loading controlled release material and preparation method thereof |
| CN105377575A (en) * | 2013-04-26 | 2016-03-02 | 太平洋纳米产品公司 | Fibrous structured amorphous silica including precipitated calcium carbonate, compositions of matter made therewith, and methods of use thereof |
| WO2016058447A1 (en) * | 2014-10-17 | 2016-04-21 | 华东理工大学 | Nano drug carrier and preparation method and use thereof |
| WO2017132410A1 (en) * | 2016-01-26 | 2017-08-03 | Frank Litvack | Compositions and uses of alpha-adrenergic agents |
| CN107161974A (en) * | 2016-03-07 | 2017-09-15 | 中国科学院上海硅酸盐研究所 | A kind of preparation method of polybasic ion codope hydroxy apatite powder material |
-
2021
- 2021-04-30 CN CN202110478939.9A patent/CN113149022B/en active Active
Patent Citations (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1245091A (en) * | 1958-12-31 | 1960-11-04 | Du Pont | Pesticide compositions, in particular herbicides, based on polychlorophenylacetic acids or on compounds of these acids |
| US6132773A (en) * | 1996-04-22 | 2000-10-17 | Rhodia Chimie | Method for preparing particles comprising a core and a silica shell |
| JP2007230794A (en) * | 2006-02-28 | 2007-09-13 | National Institute Of Advanced Industrial & Technology | Hollow particle with unique shell and its production method |
| CN101121519A (en) * | 2006-08-08 | 2008-02-13 | 中国科学院理化技术研究所 | Hollow silicon dioxide sub-micron sphere with inner core and its preparation method and use |
| CN101161250A (en) * | 2006-10-12 | 2008-04-16 | 丛繁滋 | A novel enteron pharmaceutical preparation and its preparing method |
| WO2009023697A2 (en) * | 2007-08-14 | 2009-02-19 | The Regents Of The University Of California | Hollow silica nanospheres and methods of making same |
| CN101407597A (en) * | 2007-10-12 | 2009-04-15 | 上海化工研究院 | Halogen-free flame-retardant photo-curing epoxy resin composition |
| US20110059148A1 (en) * | 2009-09-07 | 2011-03-10 | National Chiao Tung University | Flexible Drug Delivery Chip, its Fabrication Method and Uses Thereof |
| CN102451468A (en) * | 2010-10-28 | 2012-05-16 | 沈阳药科大学 | SiO2 mesoporous hollow nanosphere carrier and preparation and application thereof |
| CN102115087A (en) * | 2010-12-31 | 2011-07-06 | 张胜勇 | Method for producing silicon dioxide and calcium silicate by phosphorus residue |
| US20130225877A1 (en) * | 2012-02-29 | 2013-08-29 | Celanese International Corporation | Catalyst Having Support Containing Tin and Process for Manufacturing Ethanol |
| CN103881713A (en) * | 2012-12-20 | 2014-06-25 | 海洋王照明科技股份有限公司 | Core-shell structured calcium silicate luminescent material and preparation method thereof |
| CN105377575A (en) * | 2013-04-26 | 2016-03-02 | 太平洋纳米产品公司 | Fibrous structured amorphous silica including precipitated calcium carbonate, compositions of matter made therewith, and methods of use thereof |
| CN103920153A (en) * | 2014-05-06 | 2014-07-16 | 中国科学院上海硅酸盐研究所 | Chitosan-modified pH responsive medicine-loading controlled release material and preparation method thereof |
| WO2016058447A1 (en) * | 2014-10-17 | 2016-04-21 | 华东理工大学 | Nano drug carrier and preparation method and use thereof |
| WO2017132410A1 (en) * | 2016-01-26 | 2017-08-03 | Frank Litvack | Compositions and uses of alpha-adrenergic agents |
| CN107161974A (en) * | 2016-03-07 | 2017-09-15 | 中国科学院上海硅酸盐研究所 | A kind of preparation method of polybasic ion codope hydroxy apatite powder material |
Non-Patent Citations (7)
| Title |
|---|
| JOANNA WANG ET AL.: "Self-Reporting Photoluminescent Porous Silicon Microparticles for Drug Delivery", 《ACS APPL. MATER. INTERFACES》 * |
| LU, BQ ET AL.: "Synthesis and application in drug delivery of hollow-core-double-shell magnetic iron oxide/silica/calcium silicate nanocomposites", 《MATERIALS LETTERS》 * |
| WANG, CL ET AL.: "Investigation on raspberry-like magnetic-hollow silica nanospheres and its preliminary application for drug delivery", 《JOURNAL OF NANOPARTICLE RESEARCH 》 * |
| ZHAO, KY ET AL.: "Preparation and characterization of mesoporous calcium silicate grafted polypropylene non-woven fabric", 《MATERIALS LETTERS》 * |
| 柳丽敏: "多层化核—壳结构生物活性复相陶瓷制备及性能研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 陈超: "利用软锰矿浸渣制备4A分子筛的研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
| 魏婉: "功能化的SiO2基复合纳米药物载体的制备及性能研究", 《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113149022B (en) | 2022-07-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Sun et al. | Preparation of pH-sensitive Fe3O4@ C/carboxymethyl cellulose/chitosan composite beads for diclofenac sodium delivery | |
| Vavsari et al. | The role of SBA-15 in drug delivery | |
| JP6910954B2 (en) | Compositions, particulate matter and methods for making particulate matter | |
| CN107854449B (en) | Nano composite microsphere with drug controlled release performance and preparation method and application thereof | |
| Che et al. | Paclitaxel/gelatin coated magnetic mesoporous silica nanoparticles: Preparation and antitumor efficacy in vivo | |
| CN107233302A (en) | A kind of preparation method of nano-cellulose/poly-dopamine composite intelligent gel medicine slow-release material | |
| CN110302397A (en) | The coating mesoporous silica drug of pH responsiveness stannic oxide/graphene nano piece is double to carry composite nanoparticle and preparation method | |
| CN108126211B (en) | Preparation method of nano hybrid particles, nano hybrid particles obtained by preparation method and nano medicine | |
| Siva Gangi Reddy et al. | Fabrication of aminosilanized halloysite based floating biopolymer composites for sustained gastro retentive release of curcumin | |
| CN110801441B (en) | Capsaicin and adriamycin combined dual-pH-value-response intelligent nano drug delivery system and preparation method and application thereof | |
| CN113663069A (en) | Hollow mesoporous polydopamine nano-carrier, preparation method and application thereof | |
| CN113975235B (en) | Fucoxanthin-delivering brown alginate oligosaccharide-mesoporous silica nanocomposite | |
| CN113149022B (en) | Silica @ calcium silicate hollow nanosphere and preparation method and application thereof | |
| CN108938595B (en) | Preparation method of cationic lipid-mesoporous silicon composite nano-carrier for co-loading siRNA and chemotherapeutic drugs | |
| Idris et al. | Synthesis, characterization, and in vitro release of oxytetracycline loaded in pH-responsive CaCO3 nanoparticles | |
| CN114392248B (en) | Preparation method of anthocyanin-carrying nanoparticles | |
| CN116585290B (en) | Composite material for long-acting slow release of soluble medicine and preparation method thereof | |
| Qin et al. | Study of pH-responsive and polyethylene glycol-modified doxorubicin-loaded mesoporous silica nanoparticles for drug delivery | |
| CN113181199A (en) | PH-responsive intelligent porous magnetic nano drug delivery system for combined administration of bicalutamide and adriamycin and preparation method thereof | |
| CN101401799A (en) | Method for preparing farina microcapsule medicament | |
| CN107149683B (en) | Preparation method and application of mesoporous silica nanoparticles with bell structure | |
| CN115040496B (en) | Preparation method of hollow mesoporous polydopamine lipid-loaded soluble pigment nanoparticles | |
| KR20190043399A (en) | Method of manufacturing graphene aerogels for drug delivery | |
| CN114469862A (en) | Method for regulating and encapsulating polydopamine by cholesterol | |
| CN111514315A (en) | Method for loading medicine on tumor-targeted amorphous calcium phosphate fluorescent nano composite material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |